Fortress Biotech, Inc. - Common Stock — 분기별 재무 통계 (NASDAQ:FBIO)

Financials

영업활동으로 인한 현금 -12.91 M-19.56 M-27.56 M-6.11 M-12.54 M203.85 M 157.64 M 투자 활동으로 인한 현금 -15 M1.17 M6.09 M2.87 M00 8.96 M 재무활동으로 인한 현금 25.81 M52.14 M4.52 M15.07 M5.71 M-27.39 M -2.09 M 잉여 현금 흐름 -12.91 M-19.56 M-27.56 M-6.11 M-12.54 M203.85 M 157.64 M

Fortress Biotech, Inc. - Common Stock

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

FBIO

Financials

Fortress Biotech, Inc. - Common Stock

뉴스

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment

Fortress Biotech Stock: The PRV Catalyst That Could Reprice This Microcap (NASDAQ:FBIO)

Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

멘케스병 치료제, FDA 최초 승인

FDA approves first treatment for Menkes disease in children

FDA, Fortress Biotech의 멘케스병 치료제 PDUFA 날짜 새로 설정

FDA sets new PDUFA date for Fortress Biotech’s Menkes disease therapy

포트리스 바이오텍, 멘케스병 치료제 NDA 재신청 보고

Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates